Related references
Note: Only part of the references are listed.Clinical validation of a new commercial highly sensitive KIT D816V mutation analysis in mastocytosis
Thomas Kristensen et al.
ALLERGY (2020)
Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
Johannes Luebke et al.
LEUKEMIA (2019)
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
Mohamad Jawhar et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management
Animesh Pardanani
AMERICAN JOURNAL OF HEMATOLOGY (2019)
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
Wolfgang R. Sperr et al.
LANCET HAEMATOLOGY (2019)
Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia
Yanhong Tan et al.
LEUKEMIA RESEARCH (2018)
Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis
Georg Greiner et al.
CLINICAL CHEMISTRY (2018)
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Peter Valent et al.
BLOOD (2017)
Comparison of gDNA-based versus mRNA-based KIT D816V mutation analysis reveals large differences between blood and bone marrow in systemic mastocytosis
Thomas Kristensen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers
Mohamad Jawhar et al.
BLOOD (2017)
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+advanced systemic mastocytosis
M. Jawhar et al.
LEUKEMIA (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis
M. Jawhar et al.
LEUKEMIA (2016)
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis
Giovanna De Matteis et al.
LEUKEMIA RESEARCH (2015)
The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease
G. Hoermann et al.
ALLERGY (2014)
A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms
Francesca Fantasia et al.
ANNALS OF HEMATOLOGY (2014)
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
Philipp Erben et al.
ANNALS OF HEMATOLOGY (2014)
Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
Hye-Ran Kim et al.
PLOS ONE (2013)
Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay
Thomas Kristensen et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Share Paper
